NCT05696847View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

January 16, 2025

Study Completion Date

January 16, 2025

Conditions
Obesity
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (3)

73112

Lynn Health Science Institute, Oklahoma City

77030

Baylor College of Medicine, Houston

30331 2012

Atlanta Center of Medical Research, Atlanta

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY